Author(s):
Michela Faggioni,
Michael C Gibson,
Roxana Mehran
Added:
3 years ago
The use of non-vitamin K antagonist oral anticoagulants (NVKA) has revolutionized the antithrombotic treatment of patients with atrial fibrillation (AF), finally freeing them of the inconvenience and expense of international normalized ratio measurements. However, add to the equation the presence of coronary artery disease requiring percutaneous coronary intervention (PCI) with stent placement…
View more
Job title: Consultant Cardiologist, Bristol Heart Institute
Dr Johnson is fully trained in percutaneous coronary intervention and all aspects of general cardiology including hypertension, cardiovascular risk assessment, valvular heart disease, heart failure and arrhythmia.
He qualified from St Mary's Hospital (Imperial College, London) in 1998 and prior to commencing specialist training in the South West he undertook a period of research studying novel…
View more
Author(s):
Jelmer Westra,
Shengxian Tu
Added:
3 years ago
Physiological lesion assessment is recommended for the identification of intermediate coronary lesions that might benefit from percutaneous coronary intervention (PCI).1 The quantitative flow ratio (QFR) was developed to derive coronary physiology from angiographic images, whereas the optical flow ratio (OFR) is a more recent approach for the rapid and automated assessment of coronary physiology…
View more
Job title: Professor of Medicine
Prof Shiro Uemura is aProfessor of Medicine at theKawasaki Medical School in Kurashiki, Japan. His research interests include acute coronary syndrome, coronary heart disease, Kawasaki Disease, Percutaneous Coronary Intervention and Sick Sinus Syndrome.
Prof Shiro Uemura is a member of the editorial board for theJournal of Asian Pacific Society of Cardiology,published by Radcliffe Cardiology on…
View more
Author(s):
Donald E Cutlip
Added:
3 years ago
Stent thrombosis has been recognized as a serious complication of coronary stent placement since the procedure was first reported in the 1980s.1 Subsequent aggressive peri-procedural anti-thrombotic strategies with inpatient transition to warfarin reduced the risk to about 3.5 % for subacute (30-day) stent thrombosis,2,3 a rate that would be unacceptable by current standards and did not account…
View more
Author(s):
Keith G Oldroyd
Added:
6 years ago
In this short video, Dr Keith G Oldroyd discusses which trials best support the use of multivessel disease percutaneous coronary intervention (MVD PCI).
View more